FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890250581> ?p ?o ?g. }

• W2890250581 endingPage "205521731880081" @default.
• W2890250581 startingPage "205521731880081" @default.
• W2890250581 abstract "Background The increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasation, has been proposed as a predictive marker for treatment tolerability. However, pre-analytical procedures might impact test results, thereby limiting its clinical usability. Whether the immediate analysis of CD62L expression of peripheral blood mononuclear cells can aid treatment decision making is yet unclear. Objective To investigate the effect of various disease-modifying therapies in multiple sclerosis on CD62L expression of CD3 + CD4 + peripheral blood mononuclear cells in freshly collected blood samples. Methods We collected peripheral blood samples from patients with clinically isolated syndrome and multiple sclerosis (baseline/follow up n = 234/ n = 98) and healthy controls ( n = 51). CD62L + CD3 + CD4 + expression was analysed within 1 hour by fluorescence-activated cell sorting. Results CD62L + CD3 + CD4 + expression was significantly decreased in patients treated with natalizumab ( n = 26) and fingolimod ( n = 20) and increased with dimethyl-fumarate ( n = 15) compared to patients receiving interferon/glatiramer acetate ( n = 90/30) or no disease-modifying therapies ( n = 53) and controls ( n = 51) ( p<0.001). CD62L expression showed temporal stability during unchanged disease-modifying therapy usage, but increased after natalizumab withdrawal and decreased upon fingolimod introduction. Conclusion CD62L + CD3 + CD4 + expression is altered in patients treated with different disease-modifying therapies when measured in freshly collected samples. The clinical meaning of CD62L changes under disease-modifying therapies warrants further investigation." @default.
• W2890250581 created "2018-09-27" @default.
• W2890250581 creator A5004966845 @default.
• W2890250581 creator A5012265362 @default.
• W2890250581 creator A5024718915 @default.
• W2890250581 creator A5029974708 @default.
• W2890250581 creator A5031096409 @default.
• W2890250581 creator A5033578999 @default.
• W2890250581 creator A5041051759 @default.
• W2890250581 creator A5053839373 @default.
• W2890250581 creator A5057796353 @default.
• W2890250581 creator A5065750087 @default.
• W2890250581 creator A5072487328 @default.
• W2890250581 creator A5074181957 @default.
• W2890250581 date "2018-07-01" @default.
• W2890250581 modified "2023-10-13" @default.
• W2890250581 title "The effect of disease modifying therapies on CD62L expression in multiple sclerosis" @default.
• W2890250581 cites W1827872226 @default.
• W2890250581 cites W1898573786 @default.
• W2890250581 cites W2005024095 @default.
• W2890250581 cites W2007995268 @default.
• W2890250581 cites W2085771265 @default.
• W2890250581 cites W2112165124 @default.
• W2890250581 cites W2122545833 @default.
• W2890250581 cites W2139685556 @default.
• W2890250581 cites W2142577589 @default.
• W2890250581 cites W2153518194 @default.
• W2890250581 cites W2164250102 @default.
• W2890250581 cites W2207593706 @default.
• W2890250581 cites W2339329547 @default.
• W2890250581 cites W2343323874 @default.
• W2890250581 cites W2479624648 @default.
• W2890250581 cites W2521995838 @default.
• W2890250581 cites W2548966208 @default.
• W2890250581 cites W2612936674 @default.
• W2890250581 cites W2619143798 @default.
• W2890250581 cites W2916040650 @default.
• W2890250581 doi "https://doi.org/10.1177/2055217318800810" @default.
• W2890250581 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6149021" @default.
• W2890250581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30263146" @default.
• W2890250581 hasPublicationYear "2018" @default.
• W2890250581 type Work @default.
• W2890250581 sameAs 2890250581 @default.
• W2890250581 citedByCount "3" @default.
• W2890250581 countsByYear W28902505812019 @default.
• W2890250581 countsByYear W28902505812020 @default.
• W2890250581 countsByYear W28902505812021 @default.
• W2890250581 crossrefType "journal-article" @default.
• W2890250581 hasAuthorship W2890250581A5004966845 @default.
• W2890250581 hasAuthorship W2890250581A5012265362 @default.
• W2890250581 hasAuthorship W2890250581A5024718915 @default.
• W2890250581 hasAuthorship W2890250581A5029974708 @default.
• W2890250581 hasAuthorship W2890250581A5031096409 @default.
• W2890250581 hasAuthorship W2890250581A5033578999 @default.
• W2890250581 hasAuthorship W2890250581A5041051759 @default.
• W2890250581 hasAuthorship W2890250581A5053839373 @default.
• W2890250581 hasAuthorship W2890250581A5057796353 @default.
• W2890250581 hasAuthorship W2890250581A5065750087 @default.
• W2890250581 hasAuthorship W2890250581A5072487328 @default.
• W2890250581 hasAuthorship W2890250581A5074181957 @default.
• W2890250581 hasBestOaLocation W28902505811 @default.
• W2890250581 hasConcept C126322002 @default.
• W2890250581 hasConcept C137061746 @default.
• W2890250581 hasConcept C185592680 @default.
• W2890250581 hasConcept C197934379 @default.
• W2890250581 hasConcept C202751555 @default.
• W2890250581 hasConcept C203014093 @default.
• W2890250581 hasConcept C2776036978 @default.
• W2890250581 hasConcept C2778375690 @default.
• W2890250581 hasConcept C2778577042 @default.
• W2890250581 hasConcept C2780640218 @default.
• W2890250581 hasConcept C2781004633 @default.
• W2890250581 hasConcept C55493867 @default.
• W2890250581 hasConcept C71924100 @default.
• W2890250581 hasConcept C90924648 @default.
• W2890250581 hasConceptScore W2890250581C126322002 @default.
• W2890250581 hasConceptScore W2890250581C137061746 @default.
• W2890250581 hasConceptScore W2890250581C185592680 @default.
• W2890250581 hasConceptScore W2890250581C197934379 @default.
• W2890250581 hasConceptScore W2890250581C202751555 @default.
• W2890250581 hasConceptScore W2890250581C203014093 @default.
• W2890250581 hasConceptScore W2890250581C2776036978 @default.
• W2890250581 hasConceptScore W2890250581C2778375690 @default.
• W2890250581 hasConceptScore W2890250581C2778577042 @default.
• W2890250581 hasConceptScore W2890250581C2780640218 @default.
• W2890250581 hasConceptScore W2890250581C2781004633 @default.
• W2890250581 hasConceptScore W2890250581C55493867 @default.
• W2890250581 hasConceptScore W2890250581C71924100 @default.
• W2890250581 hasConceptScore W2890250581C90924648 @default.
• W2890250581 hasIssue "3" @default.
• W2890250581 hasLocation W28902505811 @default.
• W2890250581 hasLocation W28902505812 @default.
• W2890250581 hasLocation W28902505813 @default.
• W2890250581 hasLocation W28902505814 @default.
• W2890250581 hasOpenAccess W2890250581 @default.
• W2890250581 hasPrimaryLocation W28902505811 @default.
• W2890250581 hasRelatedWork W1532617462 @default.
• W2890250581 hasRelatedWork W2085438061 @default.

• next